Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:NTRB NASDAQ:SPAI OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.01+1.3%$2.13$0.76▼$2.73$75.83M1.39113,013 shs89,900 shsNTRBNutriband$6.52+1.6%$7.62$3.72▼$11.78$72.64M1.13138,309 shs13,005 shsSPAISafe Pro Group$6.78-1.9%$3.63$1.47▼$7.39$110.04MN/A166,522 shs398,217 shsVASOVaso$0.12-2.8%$0.12$0.11▼$0.32$21.35M1.5775,317 shs6,557 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-4.81%-2.46%-18.18%+23.75%+49.43%NTRBNutriband-0.62%+3.05%-20.57%-0.77%+15.70%SPAISafe Pro Group+13.09%+57.05%+78.09%+159.77%+690,999,900.00%VASOVaso+1.79%+8.79%+2.21%-5.45%-52.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.1784 of 5 stars0.03.00.04.23.51.70.6NTRBNutriband3.3482 of 5 stars3.55.00.00.02.81.70.6SPAISafe Pro Group0.3156 of 5 stars1.00.00.00.03.01.70.0VASOVaso1.022 of 5 stars0.05.00.00.00.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ANTRBNutriband 3.00Buy$13.0099.54% UpsideSPAISafe Pro Group 4.00Strong Buy$8.0017.99% UpsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, SPAI, APYX, and NTRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025SPAISafe Pro GroupLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.58N/AN/A$0.20 per share10.03NTRBNutriband$2.14M33.94N/AN/A$0.58 per share11.23SPAISafe Pro Group$2.17M50.52N/AN/A$0.16 per share42.38VASOVaso$86.77M0.25$0.01 per share12.15$0.15 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)NTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)SPAISafe Pro Group-$7.43M-$0.80N/A∞N/A-731.46%-328.85%-248.09%9/25/2025 (Estimated)VASOVaso$950K-$0.01N/A∞N/A-0.35%-1.14%-0.38%11/12/2025 (Estimated)Latest VASO, SPAI, APYX, and NTRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/2/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A8/14/2025Q2 2025SPAISafe Pro GroupN/A-$0.13N/A-$0.13N/A$0.09 million8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ASPAISafe Pro GroupN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95NTRBNutriband0.013.713.48SPAISafe Pro Group0.061.641.27VASOVasoN/A1.511.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%NTRBNutriband19.70%SPAISafe Pro GroupN/AVASOVasoN/AInsider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%NTRBNutriband54.09%SPAISafe Pro Group54.80%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableSPAISafe Pro Group1116.17 million7.31 millionN/AVASOVaso260175.74 million97.54 millionNot OptionableVASO, SPAI, APYX, and NTRB HeadlinesRecent News About These CompaniesVASO Central Bank Of India IFSC Code, KHEDAAugust 26 at 11:36 PM | moneycontrol.comVaso Stock Down Following Q2 Earnings as Revenue and Margins FallAugust 21, 2025 | zacks.comVaso (OTCMKTS:VASO) versus Anteris Technologies Global (NASDAQ:AVR) Head to Head ContrastAugust 21, 2025 | americanbankingnews.comPfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell DiseaseAugust 19, 2025 | pipelinereview.comPInclacumab Misses Endpoint In Sickle Cell Disease TrialAugust 19, 2025 | empr.comEPfizer's sickle cell drug fails late-stage trialAugust 15, 2025 | msn.comPfizer's sickle-cell treatment efforts falter as drug fails studyAugust 15, 2025 | msn.comVaso Corporation reports Q2 revenue $20M vs. $20.2M last yearAugust 14, 2025 | msn.comVaso Corporation Announces Financial Results for Second Quarter of 2025August 14, 2025 | finance.yahoo.comVaso Corporation Announces Financial Results for Second Quarter of 2025 | VASO Stock NewsAugust 14, 2025 | gurufocus.comFirst Patient Dosed In Clinical Trial Of Therapy For Sickle DiseaseAugust 8, 2025 | msn.comGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVASO, SPAI, APYX, and NTRB Company DescriptionsApyx Medical NASDAQ:APYX$2.00 +0.03 (+1.26%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Nutriband NASDAQ:NTRB$6.52 +0.11 (+1.64%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Safe Pro Group NASDAQ:SPAI$6.78 -0.13 (-1.88%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Safe Pro Group, Inc. engages in the provision and acquisition of security and protection products. Its products include Artificial Intelligence (AI) and Machine Learning (ML) software technology and photogrammetry analysis tools, bullet and blast resistant personal protection equipment, and aerial managed services and mission-critical uncrewed solutions. The firm operates through the following segments: Safe-PRO USA, Airborne Response, and Safe Pro AI. The company was founded by Daniyel Erdberg on December 15, 2021 and is headquartered in Aventura, FL.Vaso OTCMKTS:VASO$0.12 0.00 (-2.80%) As of 03:15 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access